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E-mail: kawakami@med.kanazawa-u.ac.jpAberrant DNA methylation is a commonly observed epigenetic
change in lung cancer. Folate has been suggested to play a role in
the homeostasis of DNA methylation and has also been implicated
in cancer chemotherapy. We investigated a possible role for folate
in DNA methylation by measuring folate concentrations in tumors
and adjacent normal tissues from 72 non-small cell lung cancer
(NSCLC) patients. These were compared to DNA methylation levels
and to clinicopathological features. Folate concentrations were
determined as the sum of 5,10-methylenetetrahydrofolate and tet-
rahydrofolate. The MethyLight assay was used to quantitate meth-
ylation in promoter regions of P16(CDKN2A), APC, CDH13, RARB,
RASSF1, RUNX3, and MYOD1. Methylation of LINE-1 repeats was
used as a surrogate for global methylation. Folate levels in tumors
correlated positively with LINE-1, CDH13, and RUNX3 methylation.
Folate concentrations and methylation of LINE-1, RASSF1, and
RUNX3 were significantly higher in adenocarcinoma compared to
squamous cell carcinoma (SCC). Two sets of array-based data
retrieved from the Gene Expression Omnibus consistently showed
that expression of FOLR1, a folate transport enzyme, and GGH, an
enzyme that prevents folate retention, were higher and lower,
respectively, in adenocarcinomas compared to SCC. This was inde-
pendently validated by quantitative RT-PCR in 26 adenocarcinomas
and 13 SCC. Our results suggest that folate metabolism plays a role
in aberrant DNA methylation in NSCLC. The histological subtype
differences in folate concentration and DNA methylation observed
here were associated with distinct expression patterns for folate
metabolizing enzymes. These findings may have clinical applica-
tions for histology-directed chemotherapy with fluoropyrimidine
and anti-folates in NSCLC. (Cancer Sci 2009; 100: 2325–2330)
L ung cancer is a leading cause of cancer death worldwide.Genetic and epigenetic aberrations accumulate throughout
lung carcinogenesis. Global hypomethylation of genomic DNA
and hypermethylation of gene promoter regions occur simulta-
neously in a wide variety of malignancies including lung can-
cer.(1,2) Little is known however about the mechanism leading to
these epigenetic alterations in human primary lung cancer.
Epidemiological studies have demonstrated that dietary folate
supplementation can prevent the development of lung cancer.(3)
Folate is an important precursor of one-carbon units required for
DNA methylation. Therefore, folate metabolism has been sug-
gested to influence epigenetic alterations in lung cancer and this
could provide a mechanism to explain the prevention of lung
cancer by folate supplementation. High folate might contribute
to the maintenance of global methylation through an adequate
supply of one-carbon units for the methylation machinery,
thereby stabilizing the genome. Although the status of dietarydoi: 10.1111/j.1349-7006.2009.01321.x
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tion,(4) an association between folate concentration and global
methylation in human lung tissue has so far not been reported.
In addition to influencing global methylation, folate metabo-
lism could also affect promoter hypermethylation, as demon-
strated previously in primary colorectal cancer. The subset of
colorectal cancers showing concurrent hypermethylation of a
large number of CpG islands has been termed the CpG island
methylator phenotype, or CIMP.(5) We previously reported high
folate concentrations in the tumor tissue of CIMP+ colorectal
cancers,(6) suggesting that folate metabolism is involved not
only in global methylation but also in promoter hypermethyla-
tion. Previous reports suggest that concurrent promoter methyla-
tion can also occur in lung cancer.(7,8) This type of lung cancer
could therefore be associated with high tissue folate concentra-
tions.
In the present study we investigated whether folate concentra-
tion correlates with DNA methylation in a series of primary
NSCLC and adjacent normal tissues. Tissue folate concentra-
tions were found to correlate with global methylation level and
with the methylation level of some promoters. However, the
most interesting observation was that lung cancers with different
histological types showed differences in folate concentrations
and global DNA methylation levels. We also observed differen-
tial expression of folate metabolizing enzymes between adeno-
carcinomas and SCC, thus providing an explanation for the
differences in folate concentration and global DNA methylation
between these histological subtypes.
Materials and Methods
Patients and samples. Matched pairs of tumor and adjacent
normal tissues were obtained from the surgical specimen of 72
patients with NSCLC. The patients comprised 51 men and 21
women and ranged in age from 36 to 86 years (mean
66.7 years). Smoking history was obtained from the health inter-
view questionnaire. Current and former smokers were classified
as ‘smoker’ (n = 51) and never smokers as ‘non-smoker’
(n = 21). No patients received neo-adjuvant chemotherapy and
folate supplementation before undergoing operation. Tissues
were frozen in liquid nitrogen immediately after resection and
stored at )80C until processed for analysis. Remaining portions
of sample were fixed with formalin and diagnosed histologically
following staining with H&E. This study was approved by the
Kanazawa University Medical Ethics Committee and written
informed consent was obtained from all patients.Cancer Sci | December 2009 | vol. 100 | no. 12 | 2325–2330
Table 1. Folate concentrations and DNA methylation in non-small
cell lung cancer and adjacent normal tissue
Normal Tumor P-value
Folate 1.87 (1.12–2.84) 3.23 (1.21–6.13) <0.01
LINE-1 88.5 (85.1–90.3) 77.8 (63.0–90.1) <0.001
p16 0.08 (0.01–0.20) 0.29 (0.03–1.45) <0.001
APC 7.42 (4.89–8.12) 3.84 (0.38–54.8) 0.252
CDH13 3.26 (1.41–4.34) 7.55 (2.53–15.7) <0.001
RARB 1.60 (0.41–4.02) 12.5 (4.96–33.0) <0.001
RASSF1 0.86 (0.24–1.94) 7.28 (0.10–40.6) <0.01
RUNX3 0.15 (0.00–0.80) 0.00 (0.00–13.2) 0.725
MYOD1 1.89 (0.89–3.20) 3.92 (1.51–12.6) <0.001
Values for the median and 25th–75th percentile range (in
parentheses) are shown for folate concentration (pmol ⁄ g protein),
LINE-1 methylation (%), and gene promoter methylation.
Table 2. Associations between tissue folate concentration and DNA




Spearman’s rho P-value Spearman’s rho P-value
LINE-1 )0.049 0.705 0.243 0.041
p16 )0.034 0.792 0.007 0.953
APC 0.110 0.390 0.083 0.490
CDH13 0.027 0.832 0.251 0.034
RARB )0.035 0.783 0.024 0.841
RASSF1 )0.076 0.550 0.081 0.499
RUNX3 )0.053 0.680 0.247 0.038
MYOD1 0.028 0.826 0.055 0.652
Spearman’s rank test was used to correlate tissue folate
concentrations with DNA methylation levels.Folate measurement. The assay for determining the reduced
folate concentration is based on entrapment of CH2FH4 into a
stable ternary complex with excess recombinant human TS
protein and excess [6-3H]FdUMP.(9) Because CH2FH4 can
potentially be dissociated to form tetrahydrofolate under these
conditions, the sum of the two folates was measured. Tumor tis-
sues were homogenized with three volumes of ice-cold 10 mM
phosphate buffer (pH 7.0) containing 2 mg ⁄mL ascorbic acid
and 40 mM 2-mercaptoethanol. After centrifugation at 105 000g,
supernatants were collected and an aliquot was used for the mea-
surement of soluble protein by the method of Bradford. The
remaining supernatant was diluted with homogenization buffer
to a final concentration of 4 mg protein ⁄mL, placed immediately
in a boiling water bath for 1 min and then centrifuged to remove
precipitated protein. The resultant supernatants were used
for folate measurement. The reaction mixture contained 5 lg
of recombinant human TS protein, 125 nM [6-3H]FdUMP
(555 GBq ⁄mmol) and 6.5 mM formaldehyde in 200 lL of
50 mM Tris-HCl buffer (pH 7.4). Fifty microliters of the superna-
tant was added to 200 lL of reaction mixture and incubated at
30C for 50 min. The radioactivity in the acid-insoluble fraction
was measured with a liquid scintillation counter (TRI-CARB
2000CA; Packard Instruments, Meriden, CT, USA).
Methylation analysis. DNA was extracted using a QIAamp
DNA mini kit according to the manufacturer’s protocol (Qiagen,
Hilden, Germany) and was then treated with bisulfite as
described previously.(10) Methylation of LINE-1 was analyzed
as a surrogate marker of global methylation using a quantitative
real-time PCR method described previously.(11) Methylation in
the promoter regions of P16(CDKN2A), APC, CDH13, RARB,
RASSF1, RUNX3, and MYOD1 was analyzed quantitatively
using the fluorescence-based real-time PCR MethyLight
assay.(12) The amount of methylated DNA sequence was nor-
malized against the amount of ALU element used as a DNA
loading control. The PMR value was calculated using DNA that
was fully methylated with SssI methylase as the positive control
reference.(13) The primer and probe sequences used for the
MethyLight assay are listed in Supplementary Table S1.
Quantitative real-time RT-PCR. Total RNA was isolated by the
single-step guanidinium isothiocyanate method using Isogen
(Nipon Gene, Toyama, Japan). Random hexamer-primed com-
plementary DNA was generated from total RNA using M-MLV
reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Quantifi-
cation of mRNA for the genes of interest and for the internal
reference gene (GAPDH) was conducted using a real-time
detection method with SYBR Premix Ex Taq (Takara Bio, Otsu,
Japan). The quantities of FOLR1 and GGH mRNA were
expressed as ratios relative to that of GAPDH mRNA. The pri-
mer sequences used for FOLR1, GGH, and GAPDH are listed in
Supplementary Table S1.
Immunohistochemistry. The representative paraffin sections of
tumor tissues were examined for expression of FOLR1 and
GGH proteins by the avidin–biotin–peroxidase complex method
with a mouse monoclonal antibody to FOLR1 (diluted 1:100;
R&D Systems, Minneapolis, MN, USA) and a chicken poly-
clonal antibody to GGH (diluted 1:100; GenWay Biotech, San
Diego, CA, USA) as described previously.(14) Biotinylated horse
anti-mouse IgG (diluted 1:200; Vector Laboratories, Burlin-
game, CA, USA) and biotinylated rabbit anti-chicken IgY
(diluted 1:200; Open Biosystems, Huntsville, AL, USA) were
used as secondary antibody to detect FOLR1 and GGH, respec-
tively.
Statistics. The results were expressed as median values (25th
percentile–75th percentile). The Mann–Whitney U test or Krus-
kal–Wallis test was used to compare levels between two or three
categorical variables, respectively. Correlations between two
numerical variables were analyzed by Spearman’s rank test. All
P-values shown are two tailed with P < 0.05 taken as signifi-2326cant. Statistical analyses were carried out using the R software
package (version 2.7.2; http://www.r-project.org/).
Results
Folate concentration and DNA methylation level in NSCLC and
adjacent normal tissue. The concentration of folate was signifi-
cantly higher in NSCLC compared to adjacent normal lung
tissue, whereas the global methylation level as indicated by
LINE-1 was lower (Table 1). Methylation levels for p16,
CDH13, RARB, RASSF1, and MYOD1 were significantly higher
in tumor tissue, but showed no difference for APC or RUNX3
(Table 1). All of the analyzed promoter regions in the genes
other than APC were more frequently methylated in tumors than
in normal tissue when the promoter methylation levels were
dichotomized using a cut-off value of 10 PMR (Supplementary
Table S2).
No significant associations were observed between folate
concentration and DNA methylation levels (global or gene
specific) in normal lung tissue (Table 2). In tumor tissue, the
folate concentration correlated positively with LINE-1,
CDH13, and RUNX3 methylation (Table 2), but not with the
other methylation sites examined. We next analyzed whether
the folate concentration in tumor tissue was associated with
concurrent hypermethylation of promoter regions. Hyperme-
thylation was defined as a PMR value of >10 and tumors
were classified as showing low (0 or 1 gene methylated),
medium (2–4 genes methylated), or high (>4 genes methylat-
ed) frequency of methylation. This analysis failed to reveal
any significant association between folate concentration anddoi: 10.1111/j.1349-7006.2009.01321.x
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Table 3. Folate concentration and DNA methylation in non-small cell
lung cancer: associations with smoking history, sex, and histological
subtype
Smoker Sex Histology
Yes No Male Female Adeno SCC
n 51 21 51 21 43 23
Folate 2.49 4.66* 2.47 4.53** 4.57 1.84**
LINE-1 70.5 85.1* 75.6 80.9 86.8 63.4***
p16 0.58 0.10** 0.68 0.15* 0.23 0.72
APC 3.51 4.16 4.30 3.15 4.91 2.78
CDH13 7.88 6.32 8.25 5.31 8.02 5.31
RARB 10.4 14.2 12.4 12.7 12.4 10.4
RASSF1 4.11 16.9 8.81 3.69 16.9 0.89*
RUNX3 0.00 0.00 0.00 0.00 0.67 0.00**
MYOD1 3.63 5.23 3.78 3.95 2.75 5.12
*P < 0.05; **P < 0.01; ***P < 0.001. Median values are shown for
folate concentration (pmol ⁄ g protein), LINE-1 methylation (%), and
promoter methylation. The Mann–Whitney U test was used for
statistical analysis. Data showing the median, 25th–75th percentile
range, and P-value are available in Supplementary Table S3. Adeno,
adenocarcinoma; n, number of patients; SCC, squamous cell
carcinoma.the frequency of gene methylation (Fig. 1). The use of different
PMR cut-off values also failed to reveal any significant associa-
tions (data not shown). These results indicate that folate concen-
trations in NSCLC tissue correlate with the global DNA
methylation level and with the methylation level of some CpG
islands, but not with the concurrent promoter hypermethylation
of multiple genes.
Positive correlations were observed between LINE-1 methyla-
tion and promoter methylation of CDH13 and RUNX3 in tumor
tissue (LINE-1 and CDH13, Spearman’s rho 0.278, P = 0.018;
LINE-1 and RUNX3, Spearman’s rho 0.299, P = 0.011). No
associations were observed between LINE-1 methylation and
promoter methylation in normal tissue.
Folate concentration and DNA methylation in normal lung
tissue: Associations with clinical and histological features.
Methylation of CDH13 in normal tissue was positively corre-
lated with patient age (Spearman’s rho 0.269, P = 0.033). The
methylation of several other genes in normal tissue also showed
trends for positive correlation with patient age (RASSF1, Spear-
man’s rho 0.234, P = 0.065; RARB, Spearman’s rho 0.225,
P = 0.077; RUNX3, Spearman’s rho 0.216, P = 0.089). These
results are consistent with previous studies that have reported
increased promoter methylation with older age in several types
of normal tissues.(15–17)
Previous studies have demonstrated an association between
smoking and promoter methylation in NSCLC.(18,19) In the cur-
rent study of normal tissue from NSCLC patients, significantly
higher methylation levels of CDH13, RARB, and MYOD1
(Mann–Whitney U test; CDH13, P = 0.021; RARB, P = 0.009;
MYOD1, P = 0.033) and marginally higher methylation levels
of p16 (Mann–Whitney U test, P = 0.064) were observed in
smokers compared to non-smokers. The methylation level for
these genes was also higher in men compared to women (Mann–
Whitney U test; CDH13, P = 0.0027; RARB, P = 0.0005;
MYOD1, P = 0.0098; p16, P = 0.049), partly due to the close
association between smoking history and sex (Chi-square test;
P < 0.0001).
Folate concentrations and the level of LINE-1 methylation in
normal lung tissue from NSCLC patients showed no association
with any clinical feature. No difference was observed in folate
concentration and methylation levels between the normal lung
tissues from patients with adenocarcinoma and those from SCC.
Folate concentration and DNA methylation in NSCLC tissue:
Associations with clinical and histological features. Patients’ age
was not correlated with folate concentration and DNA meth-














Fig. 1. Folate concentration and the frequency of promoter
hypermethylation in non-small cell lung cancer. The methylation
frequency was categorized as low (0 or 1 gene methylated; L),
medium (2–4 genes methylated; M) or high (>4 genes methylated; H).
No relationship was observed between folate concentration and the
frequency of promoter hypermethylation (Kruskal–Wallis test).
Jin et al.show the associations of folate concentration and of DNA
methylation with smoking history, sex, and tumor histology.
Tumors from non-smokers showed significantly higher folate
concentrations, higher global methylation, and lower p16
methylation. In accordance with this, NSCLC from women
showed the same associations, although the higher LINE-1
methylation level did not reach significance. CDH13 was
more frequently methylated in smokers and in men when
the promoter methylation levels were dichotomized using a
cut-off value of 10 PMR (Supplementary Table S4).
Adenocarcinomas showed significantly higher folate concen-
trations and methylation of LINE-1, RASSF1, and RUNX3 com-
pared to SCC. These associations were not due to links with
smoking history or sex, as neither of these factors was associ-
ated with histological type (Chi-square test P = 0.31 for each).
In addition, the association of histological type with folate and
LINE-1 methylation level was also observed with sub-group
analyses stratified by smoking history and sex (Table 4). No
significant association between the methylation status of
promoter regions and histological types was observed when the
promoter methylation levels were dichotomized using a cut-off
value of 10 PMR (Supplementary Table S4). Tumors with rare
histological types (adenosquamous carcinoma n = 3; large cell
carcinoma n = 2; mucoepidermoid carcinoma n = 1) were
excluded from the analysis.
mRNA and protein expression of FOLR1 and GGH in adeno-
carcinomas and SCC. The significant association observed
between folate concentration and histological type suggests that
cellular folate metabolism may differ between adenocarcinomas
and SCC. To test this hypothesis, we analyzed gene expression
data for NSCLC contained within public databases. Two array-
based datasets (Gene Expression Omnibus accession numbers
GSE 3141 and GSE 8894) were selected because of their large
sample sizes (n = 111 and n = 138, respectively). Gene expres-
sion data for the folate metabolism genes RFC1, FOLR1, FPGS,
and GGH was retrieved for analysis. In both data sets FOLR1
mRNA expression was significantly higher in adenocarcinomas
compared to SCC (Mann–Whitney U test; P < 0.0001 for each).
In contrast, GGH mRNA expression was significantly lower in
adenocarcinomas compared to SCC (Mann–Whitney U test;
P < 0.0001 in both data sets). There were no differences in the
expression of RFC1 or FPGS between the two major NSCLC
histological types.Cancer Sci | December 2009 | vol. 100 | no. 12 | 2327
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Table 4. Association of histological subtypes with folate and LINE-1 methylation levels by sub-group analyses according to smoking history
and sex
Smoker group Non-smoker group
Adeno SCC Adeno SCC
n 27 18 16 5
Folate 3.88 (0.42–6.78) 1.76 (0.00–2.61)* 4.94 (3.93–6.84) 3.23 (1.84–4.04)
LINE-1 85.7 (71.9–90.2) 60.3 (45.9–69.8)*** 90.2 (83.1–91.4) 75.4 (51.3–76.5)**
Male group Female group
Adeno SCC Adeno SCC
n 27 18 16 5
Folate 3.66 (0.00–6.35) 1.76 (0.00–2.61) 4.94 (3.93–7.38) 3.10 (1.84–3.23)*
LINE-1 86.8 (76.8–90.2) 60.3 (45.9–69.8)*** 87.7 (77.4–91.4) 75.4 (51.3–77.2)*
*P < 0.05; **P < 0.01; ***P < 0.001. Values for the median and 25th–75th percentile range (in parentheses) are shown for folate concentration
(pmol ⁄ g protein) and LINE-1 methylation (%). The Mann–Whitney U test was used for statistical analysis. Adeno, adenocarcinoma; n, number of
patients; SCC, squamous cell carcinoma.To validate the differences in FOLR1 and GGH expression
between histological types, the mRNA level of these genes was
measured by quantitative RT-PCR in 26 adenocarcinomas and






















Fig. 2. mRNA and protein expression of FOLR1 and GGH according to
the histological type of non-small cell lung cancer. (a) RNA isolated
from adenocarcinoma (Adeno; n = 26) and squamous cell carcinoma
(SCC; n = 13) was quantitatively analyzed by real-time RT-PCR. RNA
isolated from the HeLa cervical cancer cell line was used as a
standard. The mRNA expression level of FOLR1 and GGH in HeLa was
set as 1. The expression of FOLR1 was higher in adenocarcinoma than
SCC (Mann–Whitney U test; P < 0.0001), whereas the expression of
GGH was lower (Mann–Whitney U test; P < 0.001). (b) Expression and
localization of FOLR1 and GGH proteins in the tumors of Adeno and
SCC were examined by immunohistochemical staining. These proteins
were mainly expressed in tumor cells. Expression of FOLR1 was higher
in Adeno than SCC, whereas the level of GGH was higher in SCC than
Adeno. Scale bars = 100 lm.
2328two array-based datasets, significant differences in the expres-
sion of FOLR1 and GGH were observed in our NSCLC samples
(Fig. 2a). FOLR1 and GGH proteins were immunohistochemi-
cally detected in these tumor tissues. Both proteins were mainly
expressed in tumor cells. The levels of FOLR1 and GGH protein
expression examined by immunohistochemistry (Fig. 2b) were
concordant with the levels of mRNA expression measured by
the RT-PCR (Fig. 2a).
Discussion
The significant differences between normal and tumor tissues
observed in this study for global (LINE-1) and promoter methyl-
ation (Table 1) indicate the central role of aberrant DNA meth-
ylation in lung carcinogenesis. In addition, we found a positive
correlation between folate concentration and DNA methylation
of LINE-1 and of several promoter regions in NSCLC samples.
This correlation supports the notion that folate metabolism plays
a role in acquiring and ⁄or maintaining aberrant DNA methyla-
tion.
Global hypomethylation acts as a risk factor for the devel-
opment of cancer by giving rise to genomic instability.(20)
High concentrations of folate in lung tissue may contribute to
the prevention of global hypomethylation because folate is a
precursor molecule of the one-carbon units required for DNA
methylation. Dietary folate supplementation is likely to result
in higher tissue folate concentrations, therefore preventing
lung carcinogenesis by maintaining an adequate global meth-
ylation level. However, a positive correlation between folate
concentration and global methylation level in human lung tis-
sue has not been demonstrated to date. The positive correla-
tion observed in the present study between folate
concentration and LINE-1 methylation in NSCLC tissue
(Table 2) is consistent with a role for folate in the mainte-
nance of global methylation. Stronger evidence for a role of
folate supplementation in lung cancer prevention may have
been provided by an association between folate concentration
and DNA methylation level in normal lung tissue; however,
this was not observed in the present study (Table 2). The
narrow range of LINE-1 methylation in normal lung tissue
(5.2% for the 25th–75th percentiles) could explain the failure
to observe an association with folate concentration. Analysis
of a larger number of samples and ⁄or a different method of
measuring global methylation may reveal a link between
folate and global methylation in normal lung tissue.
Unlike colorectal cancer,(6) no relationship was observed
here between tissue folate concentration and the frequency of
concurrently hypermethylated genes in NSCLC (Fig. 1). Thedoi: 10.1111/j.1349-7006.2009.01321.x
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methylator phenotype in colorectal cancer, or CIMP, has well-
defined genetic and clinicopathological features, including fre-
quent Braf mutation, microsatellite instability, and mucinous
pathology.(21–23) Previous studies have suggested the existence
of a methylator phenotype in lung cancer;(7,8) however, dis-
tinctive biological characteristics for this phenotype have yet
to be described. No confirmative evidence or defined CpG
sites for methylation analysis have been put forward to dem-
onstrate the existence of a methylator phenotype in NSCLC.
Currently, the existence of a methylator phenotype defined by
concurrent promoter methylation and showing an association
with tumor folate concentrations is unlikely in NSCLC. Nev-
ertheless, further large-scale analyses of promoter methylation
are required to establish whether a methylator phenotype
exists in NSCLC.
The most important finding in this study was that folate
concentration and global DNA methylation were significantly
higher in adenocarcinoma compared to SCC. The higher
folate concentration in adenocarcinomas suggested a differ-
ence in folate metabolism and this led us to investigate
mRNA expression levels for several folate metabolizing
enzymes in relation to NSCLC histology. Two public data-
bases of array-based gene expression analysis showed consis-
tent results with regard to histologically related differences in
the expression of folate metabolizing enzymes. Quantitative
RT-PCR analysis of tumor samples from the present NSCLC
series confirmed that FOLR1 expression was higher and GGH
expression was lower in adenocarcinomas compared to SCC
(Fig. 2a). Immunohistochemical observation of FOLR1 and
GGH proteins in the tumor tissues supports that the histologi-
cal subtype differences in these mRNA expressions were
attributed to their distinct expression in tumor cells (Fig. 2b).
FOLR1 transports folate into cells(24) and its elevated expres-
sion in adenocarcinomas relative to SCC was consistent with
the higher folate concentration observed for this histological
type (Table 3). The GGH enzyme removes polyglutamate
chains from polyglutamylated folate,(25) thus facilitating the
escape of folate from within cells. The low GGH expression
level observed in adenocarcinomas is therefore also consistent
with the higher folate concentrations observed in this histo-
logical type.
Another possible explanation for the associations between
folate, global methylation, and histological type (Table 3) is a
common link with smoking history. The development of SCC
has been linked with smoking.(26,27) Smoking has also been
associated in previous reports with low folate(28) and low global
methylation.(29) However, in the present study histological type
was not associated with smoking history. Furthermore, signifi-
cant associations between histological type and folate concentra-
tion or global methylation were observed in both the smoking
and non-smoking groups (Table 4). Although the link between
histological type and folate level did not reach statistical signifi-
cance in the non-smoker group probably due to the small num-
ber of SCC cases, the results of sub-group analysis suggest that
these links were independent of smoking. Larger-scale analysis
for NSCLC cases without smoking history is needed to rule out
the influence of smoking.
The observed differences in folate metabolism between
the two major histological types of NSCLC may be of clini-
cal importance for individualized chemotherapy. A recent
clinical trial has shown that fluoropyrimidine is active for
NSCLC.(30) The activity of fluoropyrimidine can be
enhanced by simultaneous administration of folate, thereby
increasing the intracellular levels of CH2FH4 and prolonging
the inhibition of TS, the major target enzyme of fluoropyr-
imidine.(31) An in vitro study recently demonstrated that
cancer cell lines with higher basal levels of intracellular
folate also showed larger increases in CH2FH4 following theJin et al.addition of leucovorin, a folinic acid.(32) Since adenocarcino-
mas were shown in the present study to have higher folate
concentrations than SCC, the administration of folinic acid
could therefore be more effective in increasing the CH2FH4
concentration and thus providing better sensitization of these
tumors to fluoropyrimidine. This hypothesis has not been
tested to date and future clinical trials may consider whether
the histological type of NSCLC is a determinant for the
activity of fluoropyrimidine modulated with folinic acid.
In addition to fluoropyrimidine, the histological type of
NSCLC may be important for personalized chemotherapy with
anti-folates. Recent clinical studies in NSCLC have demon-
strated that pemetrexed is more effective against adenocarci-
noma than SCC.(33,34) Pemetrexed is an anti-folate that inhibits
multiple enzymes including dihydrofolate reductase and GAR-
FT as well as TS. An earlier study found that the polyglutamy-
lated form of pemetrexed inhibits TS and GARFT more potently
than the monoglutamylated form of this agent.(35) The low
expression level of GGH observed here in adenocarcinomas
(Fig. 2) could therefore contribute to higher concentrations of
longer, polyglutamylated forms of pemetrexed. This would
imply stronger inhibition of TS and GARFT by pemetrexed in
adenocarcinomas compared to SCC. The histological subtype of
NSCLC could also influence the efficacy of other anti-folates
such as raltitrexed, nolatrexed, and plevitrexed. Future clinical
studies should consider histological type when testing the activ-
ity of anti-folates against NSCLC.
In conclusion, the current study has demonstrated an asso-
ciation between folate concentration and DNA methylation
in NSCLC, thus providing evidence that folate metabolism
plays a role in the DNA methylation machinery. However,
the concurrent hypermethylation of multiple promoter regions
in NSCLC was not associated with elevated folate levels.
These results suggest that a methylator phenotype similar to
CIMP in colorectal cancer and associated with higher folate
concentrations does not occur in NSCLC. Striking histology-
related differences in folate concentration and global methyl-
ation were apparent in NSCLC and were shown to correlate
with a distinct expression pattern for two major folate
metabolizing enzymes. Differences in folate metabolism
between adenocarcinomas and SCC may be of clinical use
in NSCLC patients for histology-directed chemotherapy
using fluoropyrimidine and anti-folates.
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